Journal of Oncology Pharmacy Practice

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for more information

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kitada, N.
Right arrow Articles by Watari, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kitada, N.
Right arrow Articles by Watari, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Oncology Pharmacy Practice, Vol. 13, No. 4, 233-235 (2007)
DOI: 10.1177/1078155207079877
© 2007 SAGE Publications

Oxaliplatin-induced hypersensitivity reaction displaying marked elevation of immunoglobulin E

Noriaki Kitada, MS

Department of Hospital Pharmacy, Takarazuka Municipal Hospital; 4-5-1 Kohama, Takarazuka, Hyogo 665-0827, Japan, Department of Hospital Pharmacy, Faculty of Pharmaceutical Sciences, Kyoto Pharmaceutical University; 5 Nakauchi-cho, Misasagi, Yamashinaku, Kyoto 607-8414, Japan, nkitada{at}poppy.kyoto-phu.ac.jp

Toshiyuki Dan, MD

Department of Surgery, Takarazuka Municipal Hospital; 4-5-1 Kohama, Takarazuka, Hyogo 665-0827, Japan

Kohji Takara, PhD

Department of Hospital Pharmacy, Faculty of Pharmaceutical Sciences, Kyoto Pharmaceutical University; 5 Nakauchi-cho, Misasagi, Yamashinaku, Kyoto 607-8414, Japan

Takashi Tsuji, BS

Department of Hospital Pharmacy, Takarazuka Municipal Hospital; 4-5-1 Kohama, Takarazuka, Hyogo 665-0827, Japan

Hajime Yamasaki, MD

Department of Surgery, Takarazuka Municipal Hospital; 4-5-1 Kohama, Takarazuka, Hyogo 665-0827, Japan

Teruyoshi Yokoyama, PhD

Department of Hospital Pharmacy, Faculty of Pharmaceutical Sciences, Kyoto Pharmaceutical University; 5 Nakauchi-cho, Misasagi, Yamashinaku, Kyoto 607-8414, Japan

Masakatsu Watari, BS

Department of Hospital Pharmacy, Takarazuka Municipal Hospital; 4-5-1 Kohama, Takarazuka, Hyogo 665-0827, Japan

A 74-year-old female has been diagnosed with stage IIIB rectal cancer in 2003. Following anterior resection, she received adjuvant chemotherapy with three different regimens. In August 2005, she was started on a modified FOLFOX6 regimen, and the sixth cycle of chemotherapy induced a severe hypersensitivity reaction (HSR). Immediate cessation of the infusion resulted in a disappearance of the allergic reaction 60 min later. Blood tests just after the reaction demonstrated a marked elevation of immunoglobulin E to 300 IU L-1 (normal range: <170 IU L-1). This change implies the involvement of a type I reaction in the HSR. In addition, a drug lymphocyte stimulating test against oxaliplatin and levofolinate calcium (an isomer of leucovorin calcium) gave values of 696% and 107 % respectively, as compared with control serum. This suggests that the patient had an adverse reaction not only of type I but partly of type IV allergic reaction also. Oxaliplatin appears to have caused a HSR in this Japanese patient, and thus pharmacists, physicians, and other medical staff must keep a careful watch of a patient's clinical condition during chemotherapy including oxaliplatin. J Oncol Pharm Practice (2007) 13: 233—235.

Key Words: oxaliplatin • FOLFOX • hypersensitivity reaction • anaphylaxis • immunoglobulin E


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?